Doxycycline vs Spironolactone for Acne

Doxycycline and spironolactone both treat acne, but they attack the problem through completely different biological pathways, and the choice between them matters more than many people realize. The strongest head-to-head evidence comes from the FASCE trial, a multicenter randomized study comparing the two drugs in adult women with moderate acne, which found spironolactone nearly three times more likely to produce treatment success than doxycycline by six months. That result, combined with growing concern about long-term antibiotic use, has pushed dermatologists to rethink which drug deserves the first-line role in women’s acne.

How They Work Differently

Doxycycline is a tetracycline-class antibiotic. It reduces acne primarily by killing the bacteria that colonize clogged pores and by dampening the inflammatory response those bacteria trigger. It works relatively fast, and most people notice improvement within the first few weeks. The catch is that doxycycline does not address the underlying hormonal or oil-production signals that cause pores to clog in the first place. It manages the downstream mess without turning off the faucet.

Spironolactone takes an entirely different approach. Originally developed as a blood-pressure medication and potassium-sparing diuretic, spironolactone also blocks androgen receptors in the skin. Androgens are the hormones that ramp up sebum (oil) production, and excess sebum is a major driver of acne in adult women. By lowering the skin’s sensitivity to these hormones, spironolactone reduces oil output at its source.¹ This means it addresses one of the root causes of breakouts rather than just managing infection and inflammation after they happen.

That mechanistic difference explains much of what follows: why doxycycline tends to act faster, why spironolactone tends to hold its gains longer, and why the two drugs carry very different risk profiles.

The Head-to-Head Evidence

For years, clinicians prescribed both drugs for acne without a randomized trial directly comparing them. The FASCE study changed that. This double-blind, multicenter trial enrolled adult women with moderate acne and randomly assigned them to either spironolactone (150 mg daily) or doxycycline (100 mg daily), then followed them for up to twelve months.

At four months, the two drugs looked broadly similar. Spironolactone was 1.37 times more likely to achieve treatment success, but the difference was not statistically significant. By six months, the gap had widened considerably: spironolactone was 2.87 times more likely to produce treatment success than doxycycline, and that result was statistically significant. When the researchers looked at treatment success across all contraception methods, spironolactone achieved a 62% success rate compared with 32% for doxycycline.²

The lesion counts told a similar story. Both inflammatory and non-inflammatory lesions dropped in both groups starting around month two, but the reductions were consistently larger with spironolactone. By month six, the average reduction in non-inflammatory lesions was roughly double in the spironolactone group compared to doxycycline (about 12 fewer non-inflammatory lesions versus about 6 fewer).³ That non-inflammatory advantage makes sense given spironolactone’s ability to reduce sebum and address comedones (clogged pores that haven’t yet become red and inflamed), something antibiotics aren’t designed to do.

Why Spironolactone Pulls Ahead Over Time

The FASCE results highlight a pattern that dermatologists have long observed in practice: doxycycline tends to plateau while spironolactone keeps improving. At four months both drugs were still competitive, but by six months spironolactone had clearly separated itself. The reason traces back to the mechanism difference. Doxycycline suppresses bacterial overgrowth and inflammation, which produces a noticeable early improvement. But once the bacterial load is controlled, there is not much further the drug can push things. Meanwhile, sebum production and hormonal fluctuations continue, so the acne can creep back even while a person is still taking the antibiotic.

Spironolactone, on the other hand, takes longer to reach its full effect because it is modifying the hormonal environment of the skin. Oil glands need time to slow down, and pores need time to clear once less oil is being pumped into them. The payoff is a trajectory of continued improvement, as the FASCE data showed lesion counts still declining between months six and twelve in the spironolactone arm.⁴

This also matters for what happens when you stop. Doxycycline is typically prescribed for three to six months, and many people experience a relapse after discontinuation because the hormonal and sebum drivers were never addressed. Spironolactone, because it targets the hormonal root, tends to maintain its gains as long as you keep taking it and can be used for much longer courses without the resistance concerns that antibiotics carry.

The Antibiotic Resistance Problem

One of the strongest arguments in spironolactone’s favor has nothing to do with how well it clears skin. It is about what prolonged antibiotic courses do to the broader microbial landscape. Acne treatment has historically relied on months-long or even years-long prescriptions of oral tetracyclines like doxycycline. Multiple treatment guidelines now call for limiting the use of oral antibiotics in acne management because of growing resistance concerns, although prescribing habits have been slow to catch up.⁵

The worry is not just theoretical. Prolonged antibiotic exposure promotes resistant strains of skin bacteria, which can make future antibiotic treatment less effective for acne and potentially for more serious infections. This concern has positioned spironolactone, combined oral contraceptives, and isotretinoin as alternatives that dermatology organizations increasingly endorse as ways to reduce overall antibiotic consumption.

What Doxycycline Does to Your Gut

Beyond resistance, doxycycline takes a measurable toll on the gut microbiome. A study that profiled the effects of tetracycline-class antibiotics on gut bacteria found significant reductions in microbial diversity after doxycycline exposure, and those reductions did not fully recover even after the antibiotic was stopped. Specifically, doxycycline caused roughly a 7% decline in beneficial Lactobacillaceae and Bacteroidaceae populations, while Enterobacteriaceae (a family that includes some opportunistic pathogens) expanded by more than 10%.⁶

This is worth paying attention to because many people take doxycycline for acne during young adulthood, a period when the gut microbiome is still stabilizing and when disruptions may have longer-lasting consequences. The fact that diversity did not bounce back after the drug was withdrawn suggests these are not trivial, temporary shifts. GI symptoms like nausea, diarrhea, and stomach upset during doxycycline courses are common enough that most prescribers warn about them, but the lasting compositional changes are less often discussed.

Spironolactone, being a hormonal medication rather than an antibiotic, does not carry this gut-related baggage. Its side effects are different in character, which brings us to what each drug actually feels like to take day to day.

Side Effects You Should Expect

Doxycycline’s most common side effects are gastrointestinal: nausea, upset stomach, and diarrhea, especially if taken without food. Photosensitivity is another well-known issue. People on doxycycline burn more easily and can develop sun-related skin reactions that they never had before. The drug also carries a risk of esophageal irritation if you take a pill and lie down too quickly afterward, which is why the standard advice is to take it with a full glass of water and remain upright for at least half an hour.

Spironolactone’s side effects reflect its original purpose as a diuretic and its anti-androgen activity. Increased urination is common, especially in the first few weeks. Menstrual irregularities, including spotting between periods or changes in cycle length, are the other frequently reported issue. An 8-year follow-up study of women using spironolactone for acne found that side effects were present in about 59% of participants, with the diuretic effect and menstrual irregularities being the most common complaints. However, only 15% stopped the drug because of side effects, and no serious illnesses attributable to spironolactone were reported across over 200 person-years of exposure.⁷ Breast tenderness is another common complaint, likely related to the hormonal mechanism. Some women also report mild dizziness or lightheadedness, particularly when standing up quickly, due to the drug’s blood-pressure-lowering effect.

Neither drug’s side-effect profile is dangerous for most people, but they are qualitatively different: GI problems and sun sensitivity with doxycycline versus menstrual changes and diuretic effects with spironolactone. Your tolerance for one set over the other may legitimately influence which drug makes more sense for you.

The Potassium Question

If you’ve been prescribed spironolactone or are researching it online, you’ve probably seen warnings about potassium levels. Because the drug is a potassium-sparing diuretic, it reduces the amount of potassium your kidneys excrete, which in theory could push blood potassium dangerously high. For decades, this meant routine blood tests to monitor potassium in anyone taking spironolactone.

The evidence suggests this concern is overblown for the typical acne patient: a young, otherwise healthy woman. A study of over 1,800 potassium measurements in young women taking spironolactone for acne found a hyperkalemia rate of 0.72%, essentially identical to the 0.76% baseline rate of high potassium in the same population who were not taking the drug. When the researchers followed up on the abnormal readings, repeat testing showed normal values in nearly half the cases, suggesting lab error. In the remaining cases, no medical intervention was needed.⁸ The researchers concluded that routine potassium monitoring is unnecessary for healthy young women on spironolactone for acne.

There is an important caveat. The low-risk finding applies specifically to younger, healthy women. A retrospective study found that women aged 46 to 65 had a significantly higher rate of hyperkalemia after starting spironolactone compared with women aged 18 to 45.⁹ If you’re older, have kidney issues, take other medications that raise potassium (like certain blood-pressure drugs), or have conditions that affect kidney function, potassium monitoring remains important. For the core acne-patient demographic of women in their twenties and thirties with no other health issues, the monitoring burden appears to be more of a historical convention than a medical necessity.

Who Can Actually Take Each Drug

Doxycycline can be prescribed to virtually anyone with acne, regardless of sex. Men, women, and adolescents all tolerate it. It is also used for a wide range of non-acne conditions like rosacea and certain infections, so most clinicians are very comfortable with it. The main exceptions are pregnant or breastfeeding women (tetracyclines can affect fetal bone and teeth development) and children under eight.

Spironolactone, by contrast, is essentially limited to women. Its anti-androgen mechanism, which is precisely what makes it effective for acne, causes unacceptable side effects in men: reduced testosterone levels, breast tissue swelling, and concerns about sexual dysfunction. It is not considered an acceptable treatment option for men with acne.¹⁰ It is also contraindicated in pregnancy because blocking androgens during fetal development can interfere with the sexual differentiation of a male fetus. Women who are prescribed spironolactone for acne are generally expected to use reliable contraception.

This sex-specific limitation means that the “doxycycline vs. spironolactone” question is really a question that only applies to women. For men with moderate acne, doxycycline (or another antibiotic in its class) remains a standard oral option alongside isotretinoin for more severe cases.

Long-Term Use and Staying Clear

One of the practical realities that distinguishes these two drugs is how long you can reasonably stay on them. Doxycycline is generally prescribed for three to six months. Guidelines discourage longer courses because of antibiotic resistance concerns and the gut-microbiome effects discussed earlier. Once you stop, acne often returns unless something else, whether a topical retinoid, a hormonal treatment, or a combination regimen, is holding things in place.

Spironolactone, on the other hand, can be used for years. A case series of 403 women found that the drug continued to improve clinical outcomes and was well tolerated over extended durations.¹¹ The 8-year safety data reinforces this: across hundreds of person-years of follow-up, no serious illness was attributed to the drug.¹² For women whose acne is hormonally driven, this long-term viability is a major practical advantage. Rather than cycling through repeated antibiotic courses with diminishing returns, they can stay on a single medication that keeps working without contributing to resistance.

That said, many dermatologists still start with doxycycline as a bridge. Because spironolactone takes longer to kick in, a common strategy is to begin both drugs simultaneously, use doxycycline for the first two or three months to get inflammatory acne under control quickly, then discontinue the antibiotic and continue spironolactone as maintenance therapy. This hybrid approach tries to capture the fast-acting benefits of doxycycline while transitioning to the more sustainable, root-cause-targeting mechanism of spironolactone.

When Doxycycline Still Makes Sense

Despite the growing enthusiasm for spironolactone, there are situations where doxycycline remains the better choice or the only realistic option. If you’re a man with moderate acne, spironolactone is off the table and doxycycline is one of the few oral options between topical treatments and isotretinoin. If you need fast results for a specific event or short-term situation, doxycycline’s quicker onset is an advantage. If your acne is heavily inflammatory with lots of red, painful lesions but relatively few comedones, the antibiotic’s bacteria-targeting and anti-inflammatory action may be more appropriate than a hormonal approach.

Doxycycline also remains relevant when spironolactone is contraindicated or poorly tolerated: women who are pregnant or planning pregnancy, those who cannot tolerate menstrual irregularities, patients on medications that interact with potassium, or people with kidney disease. In these cases, a time-limited doxycycline course alongside topical treatments can still be a reasonable strategy, especially when used as a bridge to another maintenance therapy.

The broader shift in dermatology is clear, though. For adult women with hormonal or mixed acne who need ongoing treatment, spironolactone increasingly looks like the stronger long-term play. The FASCE trial gave clinicians the head-to-head data they had been waiting for, and the results landed squarely in spironolactone’s favor at six months and beyond. The antibiotic-stewardship argument adds further weight. None of this makes doxycycline obsolete; it makes its role more targeted and time-limited than it used to be.

Topical Spironolactone and Emerging Options

One development worth watching is the rise of topical spironolactone formulations. Because the drug works locally in the skin’s androgen receptors, applying it directly to the face could, in theory, deliver the anti-androgen benefits while avoiding systemic side effects like diuresis and menstrual changes. Early meta-analytic data suggests that topical spironolactone shows promise for acne treatment.¹³ If topical formulations prove effective enough in larger trials, they could open the door to using spironolactone in populations currently excluded, potentially including men, since systemic anti-androgen effects might be minimal with a topical route. That possibility is still speculative, but it signals where the field is heading: away from systemic antibiotics for acne and toward more targeted hormonal and anti-inflammatory approaches wherever possible.